Compare SLNG & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | CNTX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.0M | 102.9M |
| IPO Year | N/A | 2021 |
| Metric | SLNG | CNTX |
|---|---|---|
| Price | $5.08 | $1.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $10.00 | $5.40 |
| AVG Volume (30 Days) | 5.6K | ★ 507.0K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $72,270,000.00 | N/A |
| Revenue This Year | $7.02 | N/A |
| Revenue Next Year | $7.68 | N/A |
| P/E Ratio | $93.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.29 | $0.49 |
| 52 Week High | $8.28 | $1.55 |
| Indicator | SLNG | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.76 | 54.28 |
| Support Level | $4.92 | $0.99 |
| Resistance Level | $5.17 | $1.10 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 96.97 | 78.39 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.